Active Ingredient History
Poractant alfa is a pulmonary surfactant sold under the brand name Curosurf by Chiesi Farmaceutici. Poractant alfa is an extract of natural porcine lung surfactant. As with other surfactants, marked improvement on oxygenation may occur within minutes of the administration of poractant alfa. The new generic form of surfactant is Varasurf developed in PersisGen Co. and commercialized by ArnaGen Pharmad. It has fully comparable quality profile with Curosurf. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bronchopulmonary Dysplasia (Phase 4)
COVID-19 (Phase 2)
Ductus Arteriosus, Patent (Phase 4)
Heart Defects, Congenital (Phase 1)
Hypoplastic Left Heart Syndrome (Phase 1)
Infant, Premature (Phase 4)
Infant, Premature, Diseases (Phase 4)
Neonatology (Phase 3)
Premature Birth (Phase 3)
Respiratory Distress Syndrome (Phase 4)
Respiratory Insufficiency (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
